Fig. 3From: Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrantProgression free survival 2 in patients who received ribociclib plus fulvestrant as first-line therapyBack to article page